HCPLive Network

FDA Approves Zecuity Skin Patch to Treat Migraine

 
TUESDAY, Jan. 22 (HealthDay News) -- Zecuity, a sumatriptan iontophoretic single-use, battery-powered transdermal system, has been approved by the U.S. Food and Drug Administration for acute treatment of migraine with or without aura in adults.

Noting that migraine patients often present with additional symptoms including migraine-related nausea, Zecuity patches provide an non-oral route of administration. Zecuity patches are applied to the upper arm or thigh and, on activation, initiate transdermal delivery of 6.5 mg sumatriptan over a four-hour period.

The safety and effectiveness of Zecuity were assessed in phase 3 trials that included more than 800 patients who used more than 10,000 patches. After two hours, 18 percent of patients who used Zecuity patches had no more headache, 53 percent experienced some headache relief, and 84 percent had no more nausea. For patients who used a placebo patch, the corresponding figures were 9, 29, and 63 percent. Side effects included application site pain, tingling, itching, and discomfort (5 percent), and triptan-associated adverse events (atypical sensations, 2 percent; pain and other pressure sensations, 2 percent).

"Migraine-related nausea can be as debilitating as migraine headache pain itself," study investigator Stephen D. Silberstein, M.D., of the Jefferson Headache Center in Philadelphia, said in a statement. "Treatments bypassing the gastrointestinal tract may be the best way to treat these patients."
 

More Information

Copyright © 2013 HealthDay. All rights reserved.
 
 

Further Reading
The leading cause of cancer related deaths in both men and women is lung cancer. The 5-year survival rate of lung cancer is only 16%, as 75% of patients with lung cancer are presented with symptoms of advanced disease.
Simulations demonstrate that an excise tax on sugar-sweetened beverages would be the most effective policy for reducing child obesity, according to research published online Aug. 26 in the American Journal of Preventive Medicine.
Overconfident people are better at convincing others that they're more talented than they really are, and therefore are more likely to get promotions and reach high-level positions, according to British researchers. Their findings were published online Aug. 27 in PLOS ONE.
For actinic keratoses, photodynamic therapy is associated with improved response compared with cryotherapy, according to a meta-analysis published online Aug. 27 in JAMA Dermatology.
Progress has been made toward widespread adoption of electronic health records, although there are still barriers to adoption of advanced use of EHRs, according to a report published by the Robert Wood Johnson Foundation.
For patients with hypertension, finding the right course of treatment can be critically important especially when other health factors are taken into consideration.
One accountable care organization saved $8.5 million and received a check from Medicare for $4.2 million after 17 months. Suddenly, they had physicians clamoring to join.
More Reading